Published in Mol Pharmacol on October 27, 2004
A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A (2007) 6.04
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A (2005) 2.33
Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal (2008) 2.33
Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J (2005) 2.16
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev (2010) 1.89
CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem (2011) 1.78
Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J (2006) 1.66
Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov (2008) 1.64
Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem (2009) 1.55
Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc Natl Acad Sci U S A (2010) 1.50
Pharmacological modulation of chemokine receptor function. Br J Pharmacol (2012) 1.41
Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol (2009) 1.25
Modulation of chemokine receptor activity through dimerization and crosstalk. Cell Mol Life Sci (2009) 1.15
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol (2011) 1.09
G protein activation by the leukotriene B4 receptor dimer. Evidence for an absence of trans-activation. J Biol Chem (2008) 1.04
Bioluminescence resonance energy transfer studies reveal constitutive dimerization of the human lutropin receptor and a lack of correlation between receptor activation and the propensity for dimerization. J Biol Chem (2009) 0.99
Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers. Assay Drug Dev Technol (2010) 0.95
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
The role of transmitter diffusion and flow versus extracellular vesicles in volume transmission in the brain neural-glial networks. Philos Trans R Soc Lond B Biol Sci (2015) 0.90
Oligomerization of G-protein-coupled receptors: lessons from the yeast Saccharomyces cerevisiae. Eukaryot Cell (2005) 0.90
Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol (2013) 0.90
Emerging concepts and approaches for chemokine-receptor drug discovery. Expert Opin Drug Discov (2010) 0.89
Mechanisms regulating chemokine receptor activity. Immunology (2011) 0.89
Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor. Mol Pharmacol (2009) 0.89
Biased signaling at chemokine receptors. J Biol Chem (2015) 0.88
Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation. Proc Natl Acad Sci U S A (2014) 0.88
Cyclophilin A cooperates with MIP-2 to augment neutrophil migration. J Inflamm Res (2011) 0.86
G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand? Br J Pharmacol (2011) 0.86
Human T-cell leukemia virus type-1 Tax oncoprotein regulates G-protein signaling. Blood (2006) 0.85
Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring. Adv Wound Care (New Rochelle) (2015) 0.84
Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol Disord Drug Targets (2010) 0.84
Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity. Front Endocrinol (Lausanne) (2012) 0.84
Evidence for activity-regulated hormone-binding cooperativity across glycoprotein hormone receptor homomers. Nat Commun (2012) 0.84
The downstream regulation of chemokine receptor signalling: implications for atherosclerosis. Mediators Inflamm (2013) 0.83
Receptor-Heteromer Investigation Technology and its application using BRET. Front Endocrinol (Lausanne) (2012) 0.82
A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer. Methods Mol Biol (2013) 0.82
Chemokine receptor oligomerization and allostery. Prog Mol Biol Transl Sci (2013) 0.82
Nonpathogenic CCR2-tropic SIVrcm after serial passage and its effect on SIVmac infection of Indian rhesus macaques. Virology (2008) 0.81
Characterization of conventional and atypical receptors for the chemokine CCL2 on mouse leukocytes. J Immunol (2014) 0.80
Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Front Pharmacol (2015) 0.80
The specific monomer/dimer equilibrium of the corticotropin-releasing factor receptor type 1 is established in the endoplasmic reticulum. J Biol Chem (2014) 0.79
Mechanisms of Regulation of the Chemokine-Receptor Network. Int J Mol Sci (2017) 0.78
Consequences of ChemR23 heteromerization with the chemokine receptors CXCR4 and CCR7. PLoS One (2013) 0.78
Possible role of receptor heteromers in multiple sclerosis. J Neural Transm (Vienna) (2009) 0.77
New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model. Biochem Pharmacol (2016) 0.77
Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2. PLoS One (2016) 0.76
The triplet puzzle theory indicates extensive formation of heteromers between opioid and chemokine receptor subtypes. J Neural Transm (Vienna) (2015) 0.76
Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology (2013) 0.76
Partial agonist and biased signaling properties of the synthetic enantiomers J113863/UCB35625 at chemokine receptors CCR2 and CCR5. J Biol Chem (2016) 0.75
In vitro immunological effects of blocking CCR5 on T cells. Inflammation (2015) 0.75
Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation. Mol Endocrinol (2015) 0.75
Inhibition of CXCR3-mediated chemotaxis by the human chemokine receptor-like protein CCX-CKR. Br J Pharmacol (2013) 0.75
G Protein-coupled Receptor Biased Agonism. J Cardiovasc Pharmacol (2016) 0.75
Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 4.79
Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med (2003) 3.91
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev (2006) 2.57
Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J (2005) 2.16
Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med (2003) 2.16
Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology. J Clin Endocrinol Metab (2002) 2.00
Chemerin--a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun (2007) 2.00
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology (2005) 1.88
T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. Invest Radiol (2015) 1.85
LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev Biol (2009) 1.75
Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol (2005) 1.70
Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab (2004) 1.67
The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem (2003) 1.67
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) (2001) 1.57
Defective postnatal development of the male reproductive tract in LGR4 knockout mice. Dev Biol (2006) 1.56
Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem (2009) 1.55
Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med (2005) 1.54
Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet (2008) 1.54
Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol (2002) 1.51
Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J Invest Dermatol (2007) 1.48
Predominance of aqueous Tl(I) species in the river system downstream from the abandoned Carnoulès mine (Southern France). Environ Sci Technol (2011) 1.47
Lgr4 is required for Paneth cell differentiation and maintenance of intestinal stem cells ex vivo. EMBO Rep (2011) 1.47
Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol (2006) 1.47
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol (2009) 1.45
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem (2007) 1.45
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem (2002) 1.44
Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol (2008) 1.41
Premature ovarian aging in mice deficient for Gpr3. Proc Natl Acad Sci U S A (2005) 1.41
Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology (2005) 1.41
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell (2002) 1.39
Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther (2007) 1.39
Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol (2007) 1.38
Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J (2003) 1.35
Drosophila molting neurohormone bursicon is a heterodimer and the natural agonist of the orphan receptor DLGR2. FEBS Lett (2005) 1.35
G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol (2003) 1.30
Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol (2008) 1.29
Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol Pharmacol (2008) 1.29
Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev (2011) 1.28
A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol (2007) 1.27
Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol (2006) 1.24
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem (2007) 1.23
Characterization of a novel loss of function mutation of PAX8 in a familial case of congenital hypothyroidism with in-place, normal-sized thyroid. J Clin Endocrinol Metab (2004) 1.21
GRIS: glycoprotein-hormone receptor information system. Mol Endocrinol (2006) 1.21
RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A (2006) 1.19
Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev (2005) 1.19
Expression pattern of the orphan receptor LGR4/GPR48 gene in the mouse. Histochem Cell Biol (2005) 1.18
Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol (2009) 1.15
Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J Exp Med (2004) 1.14
Distinct recognition of OX1 and OX2 receptors by orexin peptides. J Pharmacol Exp Ther (2003) 1.13
Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J Biol Chem (2002) 1.13
Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol Pharmacol (2005) 1.12
Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm (2009) 1.09
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood (2007) 1.09
Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem (2008) 1.08
An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor. J Biol Chem (2005) 1.08
F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J Immunol (2007) 1.08
Understanding ovarian hyperstimulation syndrome. Endocrine (2005) 1.07
CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur J Immunol (2003) 1.06
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Ectopic thyroid gland causing dysphonia: imaging and molecular studies. J Clin Endocrinol Metab (2010) 1.04
Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci (2002) 1.04
Structural differences in the hinge region of the glycoprotein hormone receptors: evidence from the sulfated tyrosine residues. Mol Endocrinol (2006) 1.04
Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity. Mol Endocrinol (2005) 1.03
Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem (2002) 1.03
Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. Mol Endocrinol (2004) 1.02
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood (2010) 1.02
Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep (2013) 1.02
Formyl peptide receptor-like 2 is expressed and functional in plasmacytoid dendritic cells, tissue-specific macrophage subpopulations, and eosinophils. J Immunol (2009) 1.02
Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun (2002) 1.01
Lethal respiratory failure and mild primary hypothyroidism in a term girl with a de novo heterozygous mutation in the TITF1/NKX2.1 gene. J Clin Endocrinol Metab (2008) 1.01
CCR5 and HIV infection. Receptors Channels (2002) 1.00
Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. Eur J Pharmacol (2002) 0.99
ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia. PLoS Pathog (2011) 0.99
Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats. Invest Radiol (2016) 0.99
Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol (2008) 0.98
Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology (2008) 0.98